Polish Ophthalmology Congress Highlights with Prof. Hafezi
At the Polish Ophthalmologists Congress, Prof. Farhad Hafezi presented innovative keratoconus treatments ELZA-PACE and ECO-CAIRS in Krakow.
Mark Hillen
June 12, 2025
At the Polish Ophthalmologists Congress, Prof. Farhad Hafezi presented innovative keratoconus treatments ELZA-PACE and ECO-CAIRS in Krakow.
Nikki Hafezi, MAS IP ETHZ led the P21 program in Bukhara, combining keratoconus screening with multidisciplinary pediatric assessments for 400 children.
Dr. Emilio Torres-Netto presented ELZA-PACE cross-linking at BRASCRS 2025, a customised, tissue-preserving keratoconus vision rehabilitation method with promising clinical outcomes.
CAIRS for keratoconus: Prof Hafezi and Dr. Torres-Netto are featured in Ocular Surgery News, in which CAIRS experts highlight its role in rehabilitating highly irregular corneas.
In March 2025, Tashkent became the focal point for ophthalmology innovation as it hosted the Second International Conference on Innovative Technologies in Ophthalmology.
ELZA’s CEO, Nikki Hafezi launches a keratoconus screening initiative for children with Down syndrome in Uzbekistan, beginning in Andijan.
Who is the best eye doctor in Zurich? In Switzerland? In the world? While such questions are subjective, peer recognition provides meaningful insight. The Ophthalmologist’s Power List 2025 highlights the individuals who are currently shaping the future of eye care. Among them is Prof. Farhad Hafezi, MD, PhD, FARVO, recognized for […]
At EgSCRS, ELZA’s pyramid approach to keratoconus: ELZA-sub400, PACE, ECO-CAIRS, and AI-guided diagnostics was presented in detail.
As part of the 70th Anniversary celebration of the Andijan State Medical Institute (ASMI) in Uzbekistan, ELZA Institute CEO, Nikki Hafezi, MAS IP ETHZ, took part in a series of high-level academic and institutional events from April 28 to May 1, 2025.
Hafezi addressed the widespread reliance on a 1986 prevalence estimate that places keratoconus at 1 in 2,000—formally classifying it as rare. Yet as she highlighted, emerging epidemiological data tell a starkly different story. Keratoconus is an orphan disease, not a rare one.
